I. Welcome and Announcements (5 minutes)

II. Study Presentations (10-15 minutes each)
   A. Electronic Patient Reporting of Symptoms During Outpatient Cancer Treatment: A U.S. National Randomized Controlled Trial (“PRO-TECT”)
      Ethan Basch, MD
   B. CALGB 50801: Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography for Bulky Stage I/II Classical Hodgkin Lymphoma
      Ann S. LaCasce, MD
   C. EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
      Alice Chen, MD

III. CCDR Activities (15 minutes each)
   A. Alliance CCDR Committee Updates
      George Chang, MD
   B. NCI CCDR Updates
      Kathleen Castro, RN, MS, AOCN
C. Q&A Session  
Kathleen Castro, RN, MS, AOCN & George Chang, MD

IV. Dissemination and Implementation Committee (5 minutes)  
Diana Dickson Witmer, MD, Sarah Blair, MD, Abigail Caudle, MD

V. NCORP Investigator Meeting Update (15 minutes)  
Diane St. Germain, RN, MS

VI. Alliance Public Study Result Summaries Survey (10 minutes)  
Deb Collyar

VII. Protocol Presentations (10 minutes each)  
A. 51101: A Randomized Phase II Trial of Myeloablative Versus Non-myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma  
Tracy Batchelor, MD

B. A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial ALCHEMIST  
Jamie Chaft, MD

C. A061402: Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid after Definite Radiation Therapy  
Anuj Mahindra, MD

D. A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin As Adjuvant Therapy of Node Positive HER2 Negative Breast Cancer: The ABC Trial  
Wendy Chen, MD

E. EAQ152: Communication and Education in Tumor Profiling (COMET)  
Mary L. O’Connor, MS

F. A021302: Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study  
Jon Strasser, MD on behalf of Manish Shah, MD

VIII. Study Chair and Community Co-Chair Survey Results (5-10 minutes)  
Peggy Kemeny, MD and Jon Strasser, MD

IX. Other Business